Ve­r­a­cyte to buy C2i Ge­nomics for up to $95M, in­cludes $70M up­front

In an­nounc­ing plans on Mon­day to pay up to $95 mil­lion for C2i Ge­nomics, Ve­r­a­cyte is bet­ting that it will ex­pand fur­ther along the can­cer care con­tin­u­um.

The trans­ac­tion in­volves $70 mil­lion up­front us­ing Ve­r­a­cyte’s own shares, and up to an ad­di­tion­al $25 mil­lion in mile­stone pay­ments, payable in Ve­r­a­cyte shares or cash. The deal is ex­pect­ed to close in the first quar­ter.

Ve­r­a­cyte makes tests for guid­ing physi­cians in tough-to-treat dis­eases, in­clud­ing thy­roid, prostate, breast, blad­der and lung can­cers, as well as in­ter­sti­tial lung dis­eases. By ac­quir­ing C2I, Ve­r­a­cyte can bet­ter mon­i­tor the suc­cess of a can­cer ther­a­peu­tic or sur­gi­cal in­ter­ven­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER